Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Lumbar Intervertebral Disc Degeneration
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 13 Jun 2019
Price : $35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Intervertebral disc degeneration
- Focus Therapeutic Use
- Sponsors RNL Biostar
- 25 Apr 2018 Planned End Date changed from 1 Apr 2014 to 1 Dec 2015.
- 25 Apr 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 21 Dec 2013 New trial record